Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 18 Jul 2016 Status changed from completed to active, no longer recruiting.